| Univariate Analysis | Multivariate Analysis | |||
---|---|---|---|---|---|
Variables | OR (IC 95%) | pvalue | OR (IC 95%) | pvalue | |
HCV-RNA >500.000 IU/ml | 0.5 (0.3-0.7) | 0.0009 | 0.39 (0.24-0.66) | 0.0004 | |
PegIFN alfa-2b vs alfa-2a | 0.5 (0.3-0.9) | 0.014 | 0.5 (0.27-0.93) | 0.033 | |
Stop PegIFN | 0.1 (0.1-0-2) | <0.0001 | 0.19 (0.1-0.4) | <0.0001 | |
Stop RBV | 0.3 (0.2-0.5) | <0.0001 | 0.34 (0.17-0.69) | 0.0026 | |
PLT <130.000 cell/mm3 | 0.35 (0.2-0.6) | 0.0004 | 0.45 (0.2-0.99) | 0.048 | |
Cirrhosis | 0.6 (0.3-1.2) | 0.15 | 1.37 (0.57-3.3) | 0.47 | |
Age >45 years | 0.7 (0.45-1) | 0.11 | 0.71 (0.4-1.26) | 0.25 | |
HIV infection | 0.6 (0.4-1.1) | 0.066 | 0.85 (0.32-2.23) | 0.74 | |
RBV reduction | 1.5 (0.8-2.9) | 0.25 | Â | Â | |
PegIFN reduction | 1.2 (0.6-2.6) | 0.59 | Â | Â | |
Gender (male vs female) | 0.6 (0.4-0.9) | 0.34 | 0.64 (0.36-1.14) | 0.13 | |
HCV genotype 2 vs 3 | 0.75 (0.48-1.16) | 0.2 | 0.97 (0.5-1.8) | 0.93 | |
Variables | SVR no | SVR yes | p value | OR (IC 95%) | p value |
Weeks of treatment, mean (SD) | 20.3 (15.4) | 24.3 (12.2) | 0.0006 | 1 (0.9-1.1) | 0.22 |